Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker.

[1]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[2]  J. Eyk Overview: the maturing of proteomics in cardiovascular research. , 2011 .

[3]  Jennifer E Van Eyk,et al.  Overview: The Maturing of Proteomics in Cardiovascular Research , 2011, Circulation research.

[4]  Francisco Azuaje,et al.  Transcriptional networks characterize ventricular dysfunction after myocardial infarction: A proof-of-concept investigation , 2010, J. Biomed. Informatics.

[5]  Francisco Azuaje,et al.  Integrated protein network and microarray analysis to identify potential biomarkers after myocardial infarction , 2010, Functional & Integrative Genomics.

[6]  Francisco Azuaje,et al.  Integrative Pathway-Centric Modeling of Ventricular Dysfunction after Myocardial Infarction , 2010, PloS one.

[7]  Francisco Azuaje,et al.  Coordinated modular functionality and prognostic potential of a heart failure biomarker-driven interaction network , 2010, BMC Systems Biology.

[8]  L. Hoffmann,et al.  Effects of the endocrine disruptors atrazine and PCB 153 on the protein expression of MCF-7 human cells. , 2009, Journal of proteome research.

[9]  A. Roguin,et al.  Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice , 2009 .

[10]  David Tepper,et al.  Declining In‐Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction , 2009 .

[11]  I. Holme,et al.  Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS) , 2009, Annals of medicine.

[12]  Melanie Y. White,et al.  The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery* , 2008, Molecular & Cellular Proteomics.

[13]  I. Quaye Haptoglobin, inflammation and disease. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  R. Ferrell,et al.  Haptoglobin Genotype , 2008, Diabetes.

[15]  A. Rigby,et al.  The timing of development and subsequent clinical course of heart failure after a myocardial infarction. , 2008, European heart journal.

[16]  F. Veglia,et al.  Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage , 2008, European journal of heart failure.

[17]  J. Renaut,et al.  Quantitative proteomic analysis of short photoperiod and low-temperature responses in bark tissues of peach (Prunus persica L. Batsch) , 2008, Tree Genetics & Genomes.

[18]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[19]  Leong L Ng,et al.  Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. , 2007, European heart journal.

[20]  Francis G Spinale,et al.  Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. , 2006, Journal of cardiac failure.

[21]  I. Quaye,et al.  Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana. , 2006, Journal of atherosclerosis and thrombosis.

[22]  D. Wagner,et al.  Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. , 2006, Journal of cardiac failure.

[23]  A. Alayash Redox biology of blood. , 2004, Antioxidants & redox signaling.

[24]  S. Mao,et al.  Purification of human haptoglobin 1-1, 2-1, and 2-2 using monoclonal antibody affinity chromatography. , 2004, Protein expression and purification.

[25]  A. Alayash Oxygen therapeutics: can we tame haemoglobin? , 2004, Nature Reviews Drug Discovery.

[26]  Deborah Pinchev,et al.  Mining biomarkers in human sera using proteomic tools , 2004, Proteomics.

[27]  A. Levy Genetics of diabetic cardiovascular disease: identification of a major susceptibility gene , 2003, Acta Diabetologica.

[28]  Anderson Nl,et al.  Therapeutic potential of the plasma proteome. , 2003 .

[29]  N Leigh Anderson,et al.  Therapeutic potential of the plasma proteome. , 2003, Current opinion in molecular therapeutics.

[30]  A. Kastrati,et al.  Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. , 2002, Clinical chemistry.

[31]  P. Kemmeren,et al.  Acute‐phase protein haptoglobin is a cell migration factor involved in arterial restructuring , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[33]  D. Duprez,et al.  Haptoglobin polymorphism and peripheral arterial occlusive disease. , 1997, Atherosclerosis.

[34]  O. Smithies,et al.  Genetic Control of some Serum Proteins in Normal Humans , 1955, Nature.